Physician profile
Sarit Hovav
NPI 1326489550
$306,949.11
in general payments reported to CMS, 2019-2025
17 companies · $57K in 2025
The $57K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2021: $27K · 2022: $24K · 2023: $29K · 2024: $66K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Travel and Lodging: $3,637 · Food and Beverage: $3,024 · Education: $50.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,421.40 |
| Travel and Lodging | $3,637.16 |
| Food and Beverage | $3,023.74 |
| Education | $50.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $201,636.62 | 2021-2025 | |
| Allergan, INC. | $87,259.12 | 2019 | |
| Alkermes, INC. | $16,664.98 | 2019-2022 | |
| Tris Pharma INC | $258.93 | 2024-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.08 | 2022-2024 | Caplyta |
| Merz North America, INC. | $193.75 | 2023 | |
| Axsome Therapeutics, INC. | $170.46 | 2022-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $146.11 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $124.62 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $70.19 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $37.95 | 2019 | |
| Shire North American Group INC | $34.12 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.12 | 2019 | |
| Jazz Pharmaceuticals INC. | $31.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.91 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $16.16 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarit Hovav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.